Textiles treated with the technology have also been proven to deactivate viruses, including SARS-CoV-2 (the virus that causes COVID-19).
The company has to approach the DCGI for approval to commence the trials
The preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone
The company posted net profit of Rs.34.24 crores for the period ended June 30, 2020.
The company expects revenue growth of 10-15 per cent in the US
EPS climbs to Rs 9.25 for the quarter
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
It posted net profit of Rs.147.76 crores for the period ended June 30, 2020.
The company posted net profit of Rs.2.43 crores for the period ended June 30, 2020.
Subscribe To Our Newsletter & Stay Updated
